BACKGROUND: Abiraterone acetate (AA) is a selective oral inhibitor of Steroid-17α-Hydroxylase, for patients with castration-resistant prostate cancer.
Not all patients respond to therapy, however, there are no biomarkers predicting response to AA therapy. The aim of the present study was the identification of a biomarker for patients who are likely to respond to AA therapy.
PATIENTS AND METHODS: We measured thyroid parameters in a collective of 30 patients before and during AA therapy. For statistical analyses, paired and unpaired t-tests were used.
RESULTS: During AA therapy, responders developed a significant increase in thyroid stimulating hormone (TSH) compared to non-responders (p=0.03). In the subgroup of responders, 16 out of 21 patients (76.1%) had a significant increase in TSH level (p=0.001), suggesting that TSH increase is predictive of therapy response. Non-responders showed no change in TSH level during AA therapy.
CONCLUSION: Hypothyreosis may serve as a simple predictive biomarker for therapy response under AA therapy.
Written by:
Heidegger I, Nagele U, Pircher A, Pichler R, Horninger W, Bektic J. Are you the author?
Associate Professor of Urology, Department of Urology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria.
Reference: Anticancer Res. 2014 Jan;34(1):307-11.
PubMed Abstract
PMID: 24403479
UroToday.com mCRPC Treatment Section
